Skip to main content
Top
Published in: Medical Oncology 3/2013

01-09-2013 | Original Paper

Association between main Caspase Gene Polymorphisms and the Susceptibility and Prognosis of Colorectal Cancer

Authors: Zhiwei Wu, Ye Li, Shuying Li, Lin Zhu, Guangxiao Li, Zhifu Yu, Xiaojuan Zhao, Jie Ge, Binbin Cui, Xinshu Dong, Suli Tian, Fulan Hu, Yashuang Zhao

Published in: Medical Oncology | Issue 3/2013

Login to get access

Abstract

Caspase (CASP) 3, 8, 9 are important caspases in the apoptosis pathway and play important roles in development and progression of cancer. A case–control study with 451 colorectal cancer (CRC) patients and 631 cancer-free controls were carried out, and CRC patients followed up, to investigate the associations between three main polymorphisms and colorectal cancer risk and prognosis, and their potential interactions with environmental factors on CRC risk among Chinese people. Genotypes were determined by polymerase chain reaction–restriction fragment length polymorphism and polymerase chain reaction–single strand conformation polymorphism sequencing. Odds ratio (OR), hazard ratio (HR) and their 95 % confidence intervals (CIs) were estimated with unconditional logistic-regression and Cox proportion hazard model. Individuals harboring the CASP8 -652 6N ins/del plus del/del genotype had a slightly lower risk for CRC compared those with ins/ins genotype (adjusted OR = 0.77, 95 % CI 0.59–0.99, P = 0.04). Significant associations between CASP3 -928 GG genotype and CASP9 -1263 GG genotype and reduced risk of rectal cancer were observed (adjusted OR = 0.56, 95 % CI 0.34–0.92, P = 0.02; adjusted OR = 0.59, 95 % CI 0.36–0.95, P = 0.03, respectively). There was a marginal significant association between CASP8 -652 6N ins/del polymorphism and CRC prognosis (ins/del versus ins/ins, adjusted HR = 0.69, 95 % CI 0.48–0.99, P = 0.04). These findings suggested these polymorphisms and their combinations with dietary factors may be associated with the development of CRC. CASP8 -652 6N ins/del polymorphism may be an independent survival predictor for CRC.
Literature
1.
go back to reference Abuli A, Fernandez-Rozadilla C, Giraldez MD, Munoz J, Gonzalo V, Bessa X, et al. A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22. Br J Cancer. 2011;105(6):870–5. doi:10.1038/bjc.2011.296.PubMedCrossRef Abuli A, Fernandez-Rozadilla C, Giraldez MD, Munoz J, Gonzalo V, Bessa X, et al. A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22. Br J Cancer. 2011;105(6):870–5. doi:10.​1038/​bjc.​2011.​296.PubMedCrossRef
3.
4.
go back to reference Theodoropoulos GE, Gazouli M, Vaiopoulou A, Leandrou M, Nikouli S, Vassou E, et al. Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis. Int J Colorectal Dis. 2011;26(9):1113–8. doi:10.1007/s00384-011-1217-5.PubMedCrossRef Theodoropoulos GE, Gazouli M, Vaiopoulou A, Leandrou M, Nikouli S, Vassou E, et al. Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis. Int J Colorectal Dis. 2011;26(9):1113–8. doi:10.​1007/​s00384-011-1217-5.PubMedCrossRef
5.
go back to reference Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–62.PubMedCrossRef Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–62.PubMedCrossRef
10.
go back to reference Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11(2):255–60.PubMedCrossRef Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11(2):255–60.PubMedCrossRef
12.
go back to reference Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002;2(1):S1–15.PubMed Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002;2(1):S1–15.PubMed
13.
go back to reference Koomagi R, Volm M. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Anticancer Res. 2000;20(1B):493–6.PubMed Koomagi R, Volm M. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Anticancer Res. 2000;20(1B):493–6.PubMed
14.
go back to reference Tormanen-Napankangas U, Soini Y, Kahlos K, Kinnula V, Paakko P. Expression of caspases-3, -6 and -8 and their relation to apoptosis in non-small cell lung carcinoma. Int J Cancer. 2001;93(2):192–8. doi:10.1002/ijc.1315.PubMedCrossRef Tormanen-Napankangas U, Soini Y, Kahlos K, Kinnula V, Paakko P. Expression of caspases-3, -6 and -8 and their relation to apoptosis in non-small cell lung carcinoma. Int J Cancer. 2001;93(2):192–8. doi:10.​1002/​ijc.​1315.PubMedCrossRef
15.
go back to reference Jang JS, Kim KM, Choi JE, Cha SI, Kim CH, Lee WK, et al. Identification of polymorphisms in the Caspase-3 gene and their association with lung cancer risk. Mol Carcinog. 2008;47(5):383–90. doi:10.1002/mc.20397.PubMedCrossRef Jang JS, Kim KM, Choi JE, Cha SI, Kim CH, Lee WK, et al. Identification of polymorphisms in the Caspase-3 gene and their association with lung cancer risk. Mol Carcinog. 2008;47(5):383–90. doi:10.​1002/​mc.​20397.PubMedCrossRef
17.
go back to reference Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39(5):605–13. doi:10.1038/ng2030.PubMedCrossRef Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39(5):605–13. doi:10.​1038/​ng2030.PubMedCrossRef
20.
go back to reference Turner F, Smith G, Sachse C, Lightfoot T, Garner RC, Wolf CR, et al. Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer. Int J Cancer. 2004;112(2):259–64. doi:10.1002/ijc.20404.PubMedCrossRef Turner F, Smith G, Sachse C, Lightfoot T, Garner RC, Wolf CR, et al. Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer. Int J Cancer. 2004;112(2):259–64. doi:10.​1002/​ijc.​20404.PubMedCrossRef
21.
go back to reference Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KN. Eating patterns and risk of colon cancer. Am J Epidemiol. 1998;148(1):4–16.PubMedCrossRef Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KN. Eating patterns and risk of colon cancer. Am J Epidemiol. 1998;148(1):4–16.PubMedCrossRef
22.
go back to reference Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K, et al. Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res. 1990;50(22):7166–73.PubMed Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K, et al. Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res. 1990;50(22):7166–73.PubMed
25.
go back to reference Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, Penegar S, et al. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer. 2008;98(8):1434–6. doi:10.1038/sj.bjc.6604314.PubMedCrossRef Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, Penegar S, et al. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer. 2008;98(8):1434–6. doi:10.​1038/​sj.​bjc.​6604314.PubMedCrossRef
26.
go back to reference Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, Le Marchand L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet. 2008;40(3):259–60 (author reply 60-1). doi:10.1038/ng0308-259. Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, Le Marchand L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet. 2008;40(3):259–60 (author reply 60-1). doi:10.​1038/​ng0308-259.
27.
go back to reference Liu B, Zhang Y, Jin M, Ni Q, Liang X, Ma X, et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog. 2010;49(1):75–84. doi:10.1002/mc.20579.PubMed Liu B, Zhang Y, Jin M, Ni Q, Liang X, Ma X, et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog. 2010;49(1):75–84. doi:10.​1002/​mc.​20579.PubMed
28.
go back to reference Yin M, Yan J, Wei S, Wei Q. CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. Carcinogenesis. 2010;31(5):850–7. doi:10.1093/carcin/bgq047.PubMedCrossRef Yin M, Yan J, Wei S, Wei Q. CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. Carcinogenesis. 2010;31(5):850–7. doi:10.​1093/​carcin/​bgq047.PubMedCrossRef
29.
go back to reference Zhang F, Yang Y, Guo C, Wang Y. CASP8 -652 6N del polymorphism and cancer risk: a meta-analysis of 30 case-control studies in 50 112 subjects. Mutagenesis. 2012. doi:10.1093/mutage/ges019. Zhang F, Yang Y, Guo C, Wang Y. CASP8 -652 6N del polymorphism and cancer risk: a meta-analysis of 30 case-control studies in 50 112 subjects. Mutagenesis. 2012. doi:10.​1093/​mutage/​ges019.
30.
go back to reference Liamarkopoulos E, Gazouli M, Aravantinos G, Tzanakis N, Theodoropoulos G, Rizos S, et al. Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. Gastric Cancer. 2011;14(4):317–21. doi:10.1007/s10120-011-0045-1.PubMedCrossRef Liamarkopoulos E, Gazouli M, Aravantinos G, Tzanakis N, Theodoropoulos G, Rizos S, et al. Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. Gastric Cancer. 2011;14(4):317–21. doi:10.​1007/​s10120-011-0045-1.PubMedCrossRef
Metadata
Title
Association between main Caspase Gene Polymorphisms and the Susceptibility and Prognosis of Colorectal Cancer
Authors
Zhiwei Wu
Ye Li
Shuying Li
Lin Zhu
Guangxiao Li
Zhifu Yu
Xiaojuan Zhao
Jie Ge
Binbin Cui
Xinshu Dong
Suli Tian
Fulan Hu
Yashuang Zhao
Publication date
01-09-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0565-0

Other articles of this Issue 3/2013

Medical Oncology 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.